CMIC Group was established in 1992 as the first CRO in Japan. Today it involves in close to 80% of new drug development and filing in Japan. Over the last 25 years, CMIC Group developed its unique “Pharmaceutical Value Creator” (PVC) business model based on the abundant experience and knowledge as a CRO pioneer, and now the company offers full services that encompass entire value-chain of pharmaceutical companies, including regulatory consultation, clinical research and operational support, clinical site management, drug development and manufacturing, sales, and marketing of pharmaceutical products. CMIC Group currently has over 6,000 employees, with offices and facilities in 10 countries, including US, Japan, South Korea, China, Singapore, etc. It also serves medical device companies, academia, bio-ventures, and medical institutions.
CMIC Group continues to establish business models that create further value and contribute to greater advances in the medical industry including medical device, IVDs, and regenerative medicine. CMIC also contributes to a wide scope of health maintenance and enhancement measures incorporating prophylaxis, diagnosis, and treatment of diseases, like rare diseases.